A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Melanoma (Skin Cancer) · Melanoma Stage IIIB-IV · Cutaneous Melanoma · Unresectable Melanoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

USC Newport Beach, Newport Beach, California, United States
Contact: Study coordinator (Samantha Kwan) · Samantha.kwan@med.usc.edu · 323-365-3399
Contact: Study coordinator (Sandy Tran) · sandy.tran@med.usc.edu · 323-365-3935
UCSF, San Francisco, California, United States
Contact: Study coordinator (Katy Tsai) · Katy.Tsai@ucsf.edu · 323-865-3000
Contact: Study coordinator (Michael Wong) · Michael.Wong2@ucsf.edu
Stanford, Stanford, California, United States
Contact: Study coordinator (V Dingankar) · vaidehid@stanford.edu · 650-724-5519
Contact: Study coordinator (Lucie Cutler) · luciecut@stanford.edu
University of Colorado Anschutz, Aurora, Colorado, United States
Contact: Study coordinator (Sapna Patel) · Sapna.p.patel@cuanschutz.edu · 323-865-3000
Contact: Study coordinator (Zackry Morgan) · zackry.morgan@cuanschutz.edu
University of Colorado, Denver, Colorado, United States
Contact: Study coordinator (Kathy Prinz) · MelanomaClinicalResearch@olucdenver.onmicrosoft.com · 303-724-8822
Moffitt Cancer Center, Tampa, Florida, United States
Contact: Study coordinator (Indra Heron) · Indra.Herron@Moffitt.org · 813-745-4482
Dana Farber, Boston, Massachusetts, United States
Contact: Study coordinator (Justine Cohen) · justine_cohen@dfci.harvard.edu · 917.710.6968
Contact: Study coordinator (Linnea Drew) · linneam_drew@dfci.harvard.edu
University of New Mexico, Albuquerque, New Mexico, United States
Contact: Study coordinator (Moises Turquie) · MHarariTurquie@salud.unm.edu · 505-272-4946
Contact: Study coordinator (Mollie K Dedig) · mdedig@salud.unm.edu
UPenn, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Tara Mitchell) · Tara.Mitchell@pennmedicine.upenn.edu · 215-662-7908
Contact: Study coordinator (Carrie Bosse) · Carrie.Bosse@Pennmedicine.upenn.edu

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion

Melanoma · In-Transit Metastasis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Amsterdam, Netherlands · Groningen, Netherlands

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Melanoma · Unresectable Solid Tumors · Neoplasms

Abroad (travel likely)RecruitingPHASE1

Chicago, United States · Pittsburgh, United States

Ontario-wide Cancer TArgeted Nucleic Acid Evaluation

Breast Cancer · Lung Cancer · Colorectal Cancer

Abroad (travel likely)Recruiting

Hamilton, Canada · Kingston, Canada